S&P Futures
3,595.00 -6.50 (-0.18%) Dow Futures
28,810.00 +9.00 (+0.03%) Nasdaq Futures
10,977.00 -58.50 (-0.53%) Russell 2000 Futures
1,670.80 +1.00 (+0.06%) Crude Oil
81.56 +2.07 (+2.60%) Gold
1,672.50 +0.50 (+0.03%)
C4 Therapeutics, Inc. (CCCC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.54 |
| Open | 8.54 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 1000 |
| Day's Range | 8.53 - 9.17 |
| 52 Week Range | 4.84 - 48.75 |
| Volume | |
| Avg. Volume | 432,098 |
| Market Cap | 428.974M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Nov 08, 2022 - Nov 14, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CCCC
Related Research
- C4 Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 04/13/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat6 months agoArgus Research
- GlobeNewswire
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022WATERTOWN, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced it has received a Study May P
- GlobeNewswire
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022. Presentation Details:Event: Bank of America Securities P
- Simply Wall St.
With 63% ownership of the shares, C4 Therapeutics, Inc. (NASDAQ:CCCC) is heavily dominated by institutional owners
To get a sense of who is truly in control of C4 Therapeutics, Inc. ( NASDAQ:CCCC ), it is important to understand the...
